Abiopharma

BANCO SANTANDER S.A. (SAN)

Symbol	SAN
Name	BANCO SANTANDER S.A.
Sector	FINANCE
Region	Europe
Industry	-
Address	s/n 28660 Spain Santander Group City Av. de Cantabria
Telephone	(+34) 91 259 65 20
Fax	—
Email	—
Website	http://www.santander.com
Incorporation	ES
Incorporated On	—
Employees	—
Fiscal Year	12/31
Public Since	—
Exchanges	OTC;NASDAQ
Auditor	—
Audit Status	AUDITED
Reporting Status	U.S. Reporting: SEC Reporting
CIK	0000891478
Description	Banco Santander Central Hispano is the parent company of a group engaged in commercial and investment banking, financial products and services, including services such as: credit cards; mergers and acquisitions; stock brokerage; mortgages; mutual fund management; factoring; and asset management. Additional info from NASDAQ: Banco Santander Rio SA is an Argentina-based financial institution (the Bank) principally engaged in the banking sector. The Banks offer includes current and saving accounts, mortgage, consumer and commercial loans, fixed-term deposits, credit and debit cards, financial advisory, wealth management, banking guarantees, cash management, export and project financing, mergers and acquisition (M&A) transactions, custody, leasing, as well as securities brokerage, among others. Its banking business in structured in four areas: Personal, Small and medium-sized enterprises (SMEs), Corporate and Wholesale. In addition, the Bank provides life and casualty insurance products. Additional info from OTC: Banco Santander Central Hispano is the parent company of a group engaged in commercial and investment banking, financial products and services, including services such as: credit cards; mergers and acquisitions; stock brokerage; mortgages; mutual fund management; factoring; and asset management.

2026-08-20 07:34

Santander Expands U.S. Presence with Completion of Webster Acquisition

2026-08-19 17:51

New Form S-8 - Banco Santander, S.A. Filed: 2026-08-19 AccNo: 0000950103-26-012659 Size: 197 KB

2026-08-19 17:38

New Form S-8 - Banco Santander, S.A. Filed: 2026-08-19 AccNo: 0000950103-26-012655 Size: 200 KB

2026-08-19 17:30

New Form 424B5 - Banco Santander, S.A. Filed: 2026-08-19 AccNo: 0001193125-26-356978 Size: 2 MB

2026-08-18 09:22

New Form 424B5 - Banco Santander, S.A. Filed: 2026-08-18 AccNo: 0001193125-26-354769 Size: 2 MB

2026-08-13 16:34

Sanofi: Informations relatives au nombre de droits de vote et dactions - Juillet 2026

2026-08-13 16:34

Sanofi: Information concerning the total number of voting rights and shares - July 2026

2026-08-11 14:05

Middle-Income Americans Value In-Person Support for Major Financial Decisions, Santander US Survey Finds

2026-08-04 05:00

Communiqué de presse : MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques

2026-08-04 05:00

Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease